Description
Ngenla (somatrogon-ghla) is a groundbreaking, once-weekly injectable therapy designed to treat pediatric patients with growth hormone deficiency (pGHD). Developed through advanced biotechnological engineering, Ngenla offers a new level of convenience and efficacy for children who require growth hormone treatment. By reducing the frequency of injections from daily to weekly, Ngenla significantly eases the treatment burden, supporting better adherence and improving the quality of life for children and their families.
Approved by the U.S. Food and Drug Administration (FDA) and other global health agencies, Ngenla has quickly become a trusted option for healthcare providers managing pediatric GHD. Its innovative formulation ensures consistent therapeutic levels of growth hormone, promoting optimal growth and development.
Mechanism of Action
Ngenla is a long-acting recombinant human growth hormone analog. It is engineered by attaching three copies of the C-terminal peptide (CTP) from human chorionic gonadotropin (hCG) to the sequence of human growth hormone. This modification extends the half-life of the molecule, allowing for once-weekly administration without compromising the physiological action of the hormone.
Upon subcutaneous injection, somatrogon-ghla binds to growth hormone receptors located on various tissues throughout the body, particularly in the liver. This interaction stimulates the production of insulin-like growth factor 1 (IGF-1), a critical mediator that drives the growth of bones and tissues. The sustained release profile of Ngenla maintains steady IGF-1 levels, mimicking natural growth patterns and supporting normal development.
Reviews
There are no reviews yet.